Navigation Links
ORTHO EVRA(R) Prescribing Information Updated
Date:1/18/2008

RARITAN, N.J., Jan. 18 /PRNewswire-USNewswire/ -- Ortho Women's Health & Urology(TM), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., has updated the prescribing information for ORTHO EVRA(R) (norelgestromin/ethinyl estradiol transdermal system) to include further epidemiologic data.

The revised labeling includes two new additional estimates of relative risk (odds ratios) for venous thromboembolic events (VTE) of 1.1 (indicating no increase in risk) and 2.0 (indicating an approximate doubling of risk) in women using ORTHO EVRA compared to women using birth control pills. The previous labeling reported two estimates of relative risk for VTE of 0.9 (indicating no increase in risk) and 2.4 (indicating an approximate doubling of risk). This information is presented in a table in the WARNINGS section and is available at http://www.fda.gov and http://www.orthoevra.com. The results from all of these epidemiologic studies can be found on http://www.clinicaltrials.gov or by calling Ortho-McNeil Janssen Scientific Affairs, LLC Customer Communications Center at 1-800-526-7736.

The detailed patient information for ORTHO EVRA also has been revised to include this information in the OTHER CONSIDERATIONS BEFORE USING ORTHO EVRA section.

ORTHO EVRA is a hormonal birth control option and is safe and effective when used according to the product label. The Company consulted with the U.S. Food and Drug Administration on this label change. ORTHO EVRA, like all hormonal birth control, has risks and benefits. It is important that women speak to their health care professional to determine the option that is right for them.

ORTHO EVRA is indicated for the prevention of pregnancy in women who elect to use a transdermal patch as a method of contraception.

For more information about ORTHO EVRA, please visit http://www.orthoevra.com, call Ortho-McNeil Janssen Scientific Affairs, LLC Customer Communications Center at 1-800-526-7736 or contact your health care professional.

Important Safety Information

Serious as well as minor side effects have been reported with the use of hormonal contraceptives. Serious risks include blood clots, stroke and heart attacks. Cigarette smoking increases the risk of serious cardiovascular side effects, especially in women over 35. Women who use the contraceptive patch are strongly advised not to smoke.

The pharmacokinetic (PK) profile for the ORTHO EVRA patch is different from the PK profile for oral contraceptives in that it has higher steady state concentrations (60% higher) and lower peak concentrations (25% lower) of ethinyl estradiol (EE) compared with an oral contraceptive containing 35 mcg EE. It is not known whether there are changes in the risk of serious adverse events based on the differences in PK profiles of EE in women using ORTHO EVRA compared with women using oral contraceptives containing 35 mcg EE. Increased estrogen exposure may increase the risk of adverse events, including venous thromboembolism. (See CLINICAL PHARMACOLOGY, Transdermal versus Oral Contraceptives, BOLDED WARNING in the Package Insert).

The results of epidemiologic studies evaluating the risk of venous thromboembolism (VTE) among women using ORTHO EVRA compared to those using oral contraceptives containing 30-35 mcg EE and either levonorgestrel or norgestimate reported odds ratios ranging from 0.9 (no increase in risk) to 2.4 (approximate doubling of risk).

The Patch does not protect against HIV or sexually transmitted diseases.

Please see full U.S. Prescribing Information at http://www.orthoevra.com.

About Ortho Women's Health & Urology(TM)

Ortho Women's Health & Urology(TM), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., is a leader in the fields of women's health and urology, celebrating more than 75 years of partnering with women. Ortho Women's Health & Urology is committed to helping people live healthier lives and to meeting the needs of providers and patients with products such as ORTHO TRI-CYCLEN(R) LO (norgestimate/ethinyl estradiol), ORTHO EVRA(R) (norelgestromin/ethinyl estradiol transdermal system), and ELMIRON(R)(pentosan polysulfate sodium). For more information on these products, birth control, bladder health or general women's health issues, please visit http://www.orthowomenshealth.com.


'/>"/>
SOURCE Ortho Women?s Health & Urology
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
2. Isis Earns $5 Million Milestone Payment From Ortho-McNeil, Inc. for Initiation of Phase 1 Study of ISIS 325568
3. The OrthoGlide(TM) Medial Knee Implant Continues to be Accepted as an Alternative to Total Knee Replacement
4. Clinical Data Presented on OrthoGlide(R) Medial Knee Implant
5. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
6. Researcher Investigates Disparities in Doctor-Patient Information Exchange During Clinical Trial Offers
7. Initiation of Coverage Informational Review Issued by Scimitar Equity Research
8. Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information
9. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
10. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
11. ASCO and ASH Release Updated Guideline on the Use of Chemotherapy-Related Anemia Treatments in Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Jan. 17, 2017  EMD Serono, the biopharmaceutical business ... in the U.S. and Canada , ... joined the company as Senior Vice President and Head ... Smith will oversee the Fertility and Endocrinology businesses in ... launched its first product last year with Gidget™, a ...
(Date:1/17/2017)... PARSIPPANY, N.J. , Jan. 17, 2017 Interpace ... that provides clinically useful molecular diagnostic tests and pathology ... it has received a letter dated January 13, 2017 ... it has regained compliance with the requirement of the ... price of $1.00 per share. The letter ...
(Date:1/17/2017)... , Jan. 17, 2017 Tempus, a ... care, and University Hospitals Seidman Cancer Center have ... making genomic data, advanced molecular analysis and clinical ... physicians and healthcare providers. As ... genomic and transcriptomic sequencing and analysis for ovarian ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... ... SunView Software’s Service Smart Technology has been selected as a finalist for ... year, Pink Elephant recognizes a new product or service developed by an IT services ... opportunity. The award highlights original innovations that were released in 2016, either as a ...
(Date:1/17/2017)... ... January 17, 2017 , ... Achieve TMS ... is opening a new office in San Clemente, California this month. Achieve TMS ... Southern California, successfully treating individuals struggling with major depression. Depression impacts over 15 ...
(Date:1/17/2017)... ... January 17, 2017 , ... Surgeons from New York’s fastest ... practitioners on the latest breakthroughs in the prevention, diagnosis and treatment of the ... to eye surgeon, Jeffrey Martin, MD, FACS, Chief Executive Officer of SightMD and ...
(Date:1/17/2017)... ... January 17, 2017 , ... Wettstein ... to families and business professionals throughout central Colorado, is joining local nonprofit Aurora ... The Aurora Warms The Night organization is committed to breaking the cycle of ...
(Date:1/17/2017)... ... 2017 , ... Physicians Education Review®, LCC (PER®) announces philanthropist, ... the 34th Annual Miami Breast Cancer Conference®, on March 9-12, 2017 at the ... said, “We are delighted to have Sandra Lee join us as our keynote ...
Breaking Medicine News(10 mins):